US · SWKHL · ASSET MANAGEMENT
SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL) intrinsic value and stock valuation
$25.21as of 2026-11-21 · Mkt cap 193.77M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
SWK Holdings Corporation 9.00% Senior Notes due 2027 DCF and intrinsic value
InvestorsCraft values SWKHL with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from SWKHL’s statements →
SWK Holdings Corporation 9.00% Senior Notes due 2027 Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $40.8M | $45M | $37.8M | $41.5M | $56.2M |
| Operating income | $24M | $11.6M | $14.7M | $9.97M | $31M |
| Net income | -$-2.53M | $13.5M | $15.9M | $13.5M | $25.9M |
| EPSd | -$-208.06K | $1.08M | $1.25M | $1.05M | $2.02M |
| Operating cash flow | $27.3M | $23.1M | $14.9M | $8.2M | $34.3M |
| Capital expenditure | -$-510K | -$-140K | -$-500K | -$-300K | -$-1.08M |
| Free cash flow | $26.8M | $22.9M | $14.4M | $7.91M | $33.2M |
| Total assets | $272.4M | $332.2M | $334.3M | $299.6M | $282.7M |
| Total debt | $32.1M | $37.7M | $43.1M | $2.44M | $10K |
| Net debt | -$-10.65M | $31.7M | $38.6M | -$-3.71M | -$-42.85M |
| Total equity | $235.1M | $288.7M | $280.3M | $279.9M | $267.2M |
| Cash and short-term investments | $42.8M | $5.93M | $4.5M | $6.16M | $43.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $40.8M | $45M | $37.8M | $41.5M | $56.2M |
| Cost of revenue | $1.92M | $2.2M | $3.44M | $6.95M | $7.35M |
| Gross profit | $38.8M | $42.8M | $34.3M | $34.5M | $48.8M |
| Research and development expenses | $1.55M | $2.2M | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $14.8M | $11.5M | $11.2M | $13M | $13.6M |
| Other expenses | -$-1.5M | $17.5M | $8.44M | $11.6M | $4.15M |
| Operating expenses | $14.8M | $31.2M | $19.7M | $24.6M | $17.8M |
| Cost and expenses | $16.7M | $33.4M | $23.1M | $31.5M | $25.1M |
| Interest income | $38.4M | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $4.8M | $4.68M | $1.85M | $340K | $370K |
| Depreciation and amortization | $180K | $1.81M | $2.91M | $2.83M | $4.31M |
| Ebitda | $25.1M | $24.9M | $19.4M | $12.7M | $37.7M |
| Operating income | $24M | $11.6M | $14.7M | $9.97M | $31M |
| Total other income/expenses, net | -$-3.91M | $6.79M | -$-40K | -$-480K | $1.97M |
| Income before tax | $20.1M | $18.4M | $14.6M | $9.49M | $33M |
| Income tax expense | $22.7M | $4.88M | -$-1.27M | -$-4M | $7.08M |
| Net income | -$-2.53M | $13.5M | $15.9M | $13.5M | $25.9M |
| Weighted average shares outstanding | $12.2M | $12.4M | $12.7M | $12.8M | $12.8M |
| Weighted average diluted shares outstanding | $12.2M | $12.5M | $12.7M | $12.9M | $12.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $42.8M | $5.93M | $4.5M | $6.16M | $43.9M |
| Net receivables | $3.86M | $5.79M | $4.73M | $3.09M | $1.8M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $46.8M | $20.3M | $11.9M | $10.4M | $47.4M |
| Property, plant and equipment, net | $0.00 | $50K | $5.44M | $5.84M | $5.78M |
| Goodwill and intangible assets | $0.00 | $0.00 | $6.49M | $16.6M | $18.4M |
| Long-term investments | $180K | $580K | $50K | $80K | $3.61M |
| Total non-current assets | $225.6M | $312M | $322.4M | $289.3M | $235.2M |
| Total assets | $272.4M | $332.2M | $334.3M | $299.6M | $282.7M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $5.09M |
| Short-term debt | $0.00 | $0.00 | $0.00 | $2.44M | $10K |
| Deferred revenue | $0.00 | $1.5M | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $4.97M | $5.57M | $3.94M | $6.35M | $5.09M |
| Long-term debt | $32.1M | $37.7M | $43.1M | $0.00 | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $32.4M | $38M | $50M | $13.4M | $10.3M |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $37.3M | $43.6M | $53.9M | $19.7M | $15.4M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-4.18B | -$-4.13B | -$-4.14B | -$-4.15B | -$-4.16B |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $235.1M | $288.7M | $280.3M | $279.9M | $267.2M |
| Total investments | $180K | $580K | $50K | $80K | $4.64M |
| Total debt | $32.1M | $37.7M | $43.1M | $2.44M | $10K |
| Net debt | -$-10.65M | $31.7M | $38.6M | -$-3.71M | -$-42.85M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-2.53M | $13.5M | $15.9M | $13.5M | $25.9M |
| Depreciation and amortization | $180K | $1.81M | $2.91M | $2.83M | $4.06M |
| Stock-based compensation | $1.18M | $940K | $510K | $500K | $1.16M |
| Change in working capital | $7.03M | $530K | -$-970K | -$-3.47M | $480K |
| Accounts receivable | $1.93M | -$-1.06M | -$-1.64M | -$-1.29M | $110K |
| Inventory | $0.00 | $0.00 | -$-790K | $0.00 | -$-110K |
| Accounts payable | $1.59M | -$-1.33M | $400K | -$-1.6M | $2.16M |
| Net cash provided by operating activities | $27.3M | $23.1M | $14.9M | $8.2M | $34.3M |
| Investments in property, plant and equipment | -$-510K | -$-140K | -$-500K | -$-300K | -$-1.08M |
| Acquisitions, net | $6.9M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $68.1M | -$-10.13M | -$-48.95M | -$-43.55M | $25.8M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-3.07M | -$-6.01M | -$-6.33M | -$-1.14M | -$-370K |
| Dividends paid | -$-49.08M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-58.51M | -$-12.22M | $33.1M | -$-1.36M | -$-20.2M |
| Net change in cash | $36.8M | $690K | -$-920K | -$-36.71M | $39.9M |
| Cash at end of period | $42.8M | $5.93M | $5.24M | $6.16M | $42.9M |
| Operating cash flow | $27.3M | $23.1M | $14.9M | $8.2M | $34.3M |
| Capital expenditure | -$-510K | -$-140K | -$-500K | -$-300K | -$-1.08M |
| Free cash flow | $26.8M | $22.9M | $14.4M | $7.91M | $33.2M |
Line items
Line items
Line items
About SWK Holdings Corporation 9.00% Senior Notes due 2027
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
- CEO
- Jody. D Staggs
- Employees
- 24
- Beta
- 0.06
Explore
Frequently asked questions
What is the intrinsic value of SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL)?
SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SWKHL undervalued?
SWKHL trades at a price of $25.21 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.